Are you over 18 and want to see adult content?
More Annotations
![A complete backup of murman-climbing.ru](https://www.archivebay.com/archive2/78901b2f-51ee-4b5c-b5b6-08d966c6c836.png)
A complete backup of murman-climbing.ru
Are you over 18 and want to see adult content?
![A complete backup of corruptionwatch.org.za](https://www.archivebay.com/archive2/e9e4345b-0237-464e-ae60-40088c0bd9e6.png)
A complete backup of corruptionwatch.org.za
Are you over 18 and want to see adult content?
![A complete backup of coloradocollege.edu](https://www.archivebay.com/archive2/e35e5118-c2a0-4554-9d5d-eeb45f2d0868.png)
A complete backup of coloradocollege.edu
Are you over 18 and want to see adult content?
![A complete backup of needlenthread.com](https://www.archivebay.com/archive2/ea57e6cc-85e3-42b8-881b-33dafbb8ce19.png)
A complete backup of needlenthread.com
Are you over 18 and want to see adult content?
![A complete backup of asian-nation.org](https://www.archivebay.com/archive2/d72fa4ee-4722-4bab-97d2-620be3227b46.png)
A complete backup of asian-nation.org
Are you over 18 and want to see adult content?
![A complete backup of sunnyislesbeachmiami.com](https://www.archivebay.com/archive2/9b188ea9-4677-4013-a044-5db4e691a7ca.png)
A complete backup of sunnyislesbeachmiami.com
Are you over 18 and want to see adult content?
![A complete backup of deliciouslysavvy.com](https://www.archivebay.com/archive2/81b1e5a9-c55e-4310-b01a-94914ff01dc8.png)
A complete backup of deliciouslysavvy.com
Are you over 18 and want to see adult content?
Favourite Annotations
![The domain name rapidadviser.com is for sale | DAN.COM](https://www.archivebay.com/archive/d8c7d0c6-472d-43b5-9999-eace12630c51.png)
The domain name rapidadviser.com is for sale | DAN.COM
Are you over 18 and want to see adult content?
![New and Like New Packaging and Processing Machinery - Frain Industries](https://www.archivebay.com/archive/e6d7f4c2-5dff-4b8d-a4b4-8ab2bfa0a264.png)
New and Like New Packaging and Processing Machinery - Frain Industries
Are you over 18 and want to see adult content?
![Deutsche-Autopflege.de | Online Shop für die professionelle Autopflege](https://www.archivebay.com/archive/6bc1d133-5069-4040-b334-2d97d3013f71.png)
Deutsche-Autopflege.de | Online Shop für die professionelle Autopflege
Are you over 18 and want to see adult content?
![Theory Of Evolution](https://www.archivebay.com/archive/3218e0cc-e746-4668-a3c4-30ad26302ad6.png)
Theory Of Evolution
Are you over 18 and want to see adult content?
![Prints, Decor, Framing, Presentation & Desktop, Calendars, Cards, Marketing - Onelab Pro](https://www.archivebay.com/archive/38a46ef5-9da9-443c-884c-5f59d6e105dc.png)
Prints, Decor, Framing, Presentation & Desktop, Calendars, Cards, Marketing - Onelab Pro
Are you over 18 and want to see adult content?
![A complete backup of restaurantefeitoria.com](https://www.archivebay.com/archive/06d4207e-e331-4122-8cbb-98d2e7413d46.png)
A complete backup of restaurantefeitoria.com
Are you over 18 and want to see adult content?
Text
WORKOUR STAFF
We STUDY ways to improve the care cancer patients receive, and improve quality of life for survivors once initial treatment ends - relieving pain, promoting physical and mental health, and creating better end-of-life care. GIVE. Jo Horn, President & CEO, The Hope SWOG SPRING 2021 VIRTUAL GROUP MEETING RECORDINGS Thursday Meetings: April 22, 2021. Breast Committee. Cancer Care Delivery Committee. Early Therapeutics & Rare Cancers Committee. GI Committee. GU Committee. Leukemia Committee. Palliative & End of Life Care Committee. S1912CD Kick-Off Meeting. SPRING 2021 SWOG VIRTUAL GROUP MEETING RXPONDER RESULTS ANNOUNCED AT 2020 SABCS This is the first evidence in a randomized phase III trial that postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to one to three lymph nodes can safely forgo chemotherapy if their recurrence score on a genomic tumor tissue test is 25 or less. The trial also demonstrated, after a median of five years of follow-up, that premenopausal women with the sameS1823 | SWOG
Activated. 05/01/2021. Open. Phase. III. S1937. SWOG Clinical Trial Number. A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. Research Committee (s)S1802 | SWOG
Pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. *Pts must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed. Any prior therapy for benign conditions are acceptable. *Pts must have evidence of metastatic disease on technetium bone scan and CT or MRI within 42days
MEMORANDUM - HOMEPAGE Protocol Windows • Scheduled procedures and assessments (treatment administration, toxicity assessment for continuous treatment, disease assessment, specimenS2001 | SWOG
Accrual. 1 %. Abbreviated Title. Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects. Status Notes. MYELOMATCH SET TO MAKE ITS MAKE ITS MARK Group Chair. Next year, we expect to launch a new master protocol – MyeloMATCH, an umbrella trial that will test treatments for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Get ready. This trial is truly trailblazing. Dr. Harry Erba, our long-time leukemia committee chair, has taken a lot of lessons from past SWOGand
NON MUSCLE INVASIVE BLADDER CANCER 4/9/2018 1 Non-Muscle-Invasive Bladder Cancer Peter C.V. Black, M.D. S1605 Study Chair University of British Columbia – VancouverProstate Centre
HOMEPAGE | SWOGABOUTTHE SWOG NETWORKNEWS & EVENTSCLINICAL TRIALSHOW WEWORKOUR STAFF
We STUDY ways to improve the care cancer patients receive, and improve quality of life for survivors once initial treatment ends - relieving pain, promoting physical and mental health, and creating better end-of-life care. GIVE. Jo Horn, President & CEO, The Hope SWOG SPRING 2021 VIRTUAL GROUP MEETING RECORDINGS Thursday Meetings: April 22, 2021. Breast Committee. Cancer Care Delivery Committee. Early Therapeutics & Rare Cancers Committee. GI Committee. GU Committee. Leukemia Committee. Palliative & End of Life Care Committee. S1912CD Kick-Off Meeting. SPRING 2021 SWOG VIRTUAL GROUP MEETING RXPONDER RESULTS ANNOUNCED AT 2020 SABCS This is the first evidence in a randomized phase III trial that postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to one to three lymph nodes can safely forgo chemotherapy if their recurrence score on a genomic tumor tissue test is 25 or less. The trial also demonstrated, after a median of five years of follow-up, that premenopausal women with the sameS1823 | SWOG
Activated. 05/01/2021. Open. Phase. III. S1937. SWOG Clinical Trial Number. A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. Research Committee (s)S1802 | SWOG
Pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. *Pts must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed. Any prior therapy for benign conditions are acceptable. *Pts must have evidence of metastatic disease on technetium bone scan and CT or MRI within 42days
MEMORANDUM - HOMEPAGE Protocol Windows • Scheduled procedures and assessments (treatment administration, toxicity assessment for continuous treatment, disease assessment, specimenS2001 | SWOG
Accrual. 1 %. Abbreviated Title. Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects. Status Notes. MYELOMATCH SET TO MAKE ITS MAKE ITS MARK Group Chair. Next year, we expect to launch a new master protocol – MyeloMATCH, an umbrella trial that will test treatments for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Get ready. This trial is truly trailblazing. Dr. Harry Erba, our long-time leukemia committee chair, has taken a lot of lessons from past SWOGand
NON MUSCLE INVASIVE BLADDER CANCER 4/9/2018 1 Non-Muscle-Invasive Bladder Cancer Peter C.V. Black, M.D. S1605 Study Chair University of British Columbia – VancouverProstate Centre
SPRING 2021 SWOG VIRTUAL GROUP MEETING SWOG's Spring 2021 Virtual Group Meeting will take place April 19-23. On-line registration is now open via the registration link below. *Note: To ensure we use the most appropriate virtual platform for each session, please register for each meeting that you plan to attend.INSTITUTIONS
Search by name, institution number, universal NCI code, partial word,city
S1826 | SWOG
S1826. SWOG Clinical Trial Number. A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. ResearchS1937 | SWOG
S1937. SWOG Clinical Trial Number. A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. Research Committee (s) Genitourinary Cancer. Activated. 02/16/2021. 0% Accrual.
S1931 | SWOG
SWOG Clinical Trial Number. A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. ResearchCommittee (s)
CTSU/EA2201
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced RectalAdenocarcinoma
POLICIES & PROCEDURES Policy 26. The SWOG Radiation Therapy Quality Assurance Committee (4/2019) Policy 27. Bone Marrow and Stem Cell Transplantation Guidelines for Institution Approval (5/2014) Policy 28. Policy Deleted (no download available) Policy 29. Roster of Investigators MaintenancePolicies
S1806 | SWOG
SWOG Clinical Trial Number. A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. ResearchCommittee (s)
CTSU/EAA171
Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)CTSU/EA2197
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial HOMEPAGE | SWOGABOUTTHE SWOG NETWORKNEWS & EVENTSCLINICAL TRIALSHOW WEWORKOUR STAFF
We STUDY ways to improve the care cancer patients receive, and improve quality of life for survivors once initial treatment ends - relieving pain, promoting physical and mental health, and creating better end-of-life care. GIVE. Jo Horn, President & CEO, The Hope SWOG SPRING 2021 VIRTUAL GROUP MEETING RECORDINGS Thursday Meetings: April 22, 2021. Breast Committee. Cancer Care Delivery Committee. Early Therapeutics & Rare Cancers Committee. GI Committee. GU Committee. Leukemia Committee. Palliative & End of Life Care Committee. S1912CD Kick-Off Meeting. SPRING 2021 SWOG VIRTUAL GROUP MEETINGS1826 | SWOG
S1826. SWOG Clinical Trial Number. A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. ResearchS1802 | SWOG
Pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. *Pts must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed. Any prior therapy for benign conditions are acceptable. *Pts must have evidence of metastatic disease on technetium bone scan and CT or MRI within 42days
POLICIES & PROCEDURES Policy 26. The SWOG Radiation Therapy Quality Assurance Committee (4/2019) Policy 27. Bone Marrow and Stem Cell Transplantation Guidelines for Institution Approval (5/2014) Policy 28. Policy Deleted (no download available) Policy 29. Roster of Investigators MaintenancePolicies
S1801 | SWOG
Note: Planned surgery must be documented on the S1801 Planned Surgery Form. 2. Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site.LUNGMAP | SWOG
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST. This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in NON MUSCLE INVASIVE BLADDER CANCER 4/9/2018 1 Non-Muscle-Invasive Bladder Cancer Peter C.V. Black, M.D. S1605 Study Chair University of British Columbia – VancouverProstate Centre
S1418/BR006
A serum TSH must be obtained within 28 days prior to Step 2 reg to obtain a baseline value. Pts must have adequate bone marrow function as evidenced by all of the following: ANC >/= 1,500/mcL; platelets >/= 100,000/mcL; Hemoglobin >/= 9 g/dL. These HOMEPAGE | SWOGABOUTTHE SWOG NETWORKNEWS & EVENTSCLINICAL TRIALSHOW WEWORKOUR STAFF
We STUDY ways to improve the care cancer patients receive, and improve quality of life for survivors once initial treatment ends - relieving pain, promoting physical and mental health, and creating better end-of-life care. GIVE. Jo Horn, President & CEO, The Hope SWOG SPRING 2021 VIRTUAL GROUP MEETING RECORDINGS Thursday Meetings: April 22, 2021. Breast Committee. Cancer Care Delivery Committee. Early Therapeutics & Rare Cancers Committee. GI Committee. GU Committee. Leukemia Committee. Palliative & End of Life Care Committee. S1912CD Kick-Off Meeting. SPRING 2021 SWOG VIRTUAL GROUP MEETINGS1826 | SWOG
S1826. SWOG Clinical Trial Number. A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. ResearchS1802 | SWOG
Pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. *Pts must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed. Any prior therapy for benign conditions are acceptable. *Pts must have evidence of metastatic disease on technetium bone scan and CT or MRI within 42days
POLICIES & PROCEDURES Policy 26. The SWOG Radiation Therapy Quality Assurance Committee (4/2019) Policy 27. Bone Marrow and Stem Cell Transplantation Guidelines for Institution Approval (5/2014) Policy 28. Policy Deleted (no download available) Policy 29. Roster of Investigators MaintenancePolicies
S1801 | SWOG
Note: Planned surgery must be documented on the S1801 Planned Surgery Form. 2. Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site.LUNGMAP | SWOG
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST. This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in NON MUSCLE INVASIVE BLADDER CANCER 4/9/2018 1 Non-Muscle-Invasive Bladder Cancer Peter C.V. Black, M.D. S1605 Study Chair University of British Columbia – VancouverProstate Centre
S1418/BR006
A serum TSH must be obtained within 28 days prior to Step 2 reg to obtain a baseline value. Pts must have adequate bone marrow function as evidenced by all of the following: ANC >/= 1,500/mcL; platelets >/= 100,000/mcL; Hemoglobin >/= 9 g/dL. These COVID-19 INFORMATION CLEARINGHOUSE SWOG Communications *LATEST Memorandum January 25, 2021 Guidance on SWOG Trials and COVID-19 Vaccines. SWOG Active Protocol Specimen Guidance April 22, 2021. SWOG Lab and Bank Status June 1, 2021. Memorandum July 30, 2020 Canadian Cancer Trials Group Collection of COVID-19 Test Results. Form June 26, 2020 PDF Version of SWOG COVID-19 Diagnosis and ProtocolCONTACT US | SWOG
SWOG Cancer Research Network conducts business in four U.S. offices: - The group chair’s office in Portland, OR - The operations office in San Antonio, TX - The statistics and data management center in Seattle, WA, and - The Hope Foundation for Cancer Research, its public charity, in Ann Arbor, MI Contact us at the email addresses below, or get more contact information on our Staff Directory SPRING 2021 SWOG VIRTUAL GROUP MEETING SWOG's Spring 2021 Virtual Group Meeting will take place April 19-23. On-line registration is now open via the registration link below. *Note: To ensure we use the most appropriate virtual platform for each session, please register for each meeting that you plan to attend. POLICIES & PROCEDURES Policy 26. The SWOG Radiation Therapy Quality Assurance Committee (4/2019) Policy 27. Bone Marrow and Stem Cell Transplantation Guidelines for Institution Approval (5/2014) Policy 28. Policy Deleted (no download available) Policy 29. Roster of Investigators MaintenancePolicies
INSTITUTIONS
Search by name, institution number, universal NCI code, partial word,city
S1803 | SWOG
Publication Information Expand/Collapse. 2020. PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY): SWOG S1803. STOPPING SEXUAL INTIMIDATION: OUR NEXT STEPS As they are for ASCO, AACR, and the other cooperative cancer research networks, sexual harassment and coercion are 100% contrary to SWOG’s core values, and they will not be casually brushed aside or toleratedat any level.
S1007 | SWOG
First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative breast cancer with recurrence score (RS) of 25 or less: SWOG S1007CTSU/EAA171
Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) WAKE FOREST UNIVERSITY AT CLEMMONS 2311 Lewisville-Clemmons Road, Clemmons NC 27012 United States Skip to main content Google Tag Manager Spring 2021 Virtual Meeting Recordings RECORDINGS FROM THE OPEN SESSIONS OF THE SWOG SPRING 2021 VIRTUAL GROUP MEETING ARE NOW AVAILABLE. IF YOU WEREN'T ABLE TO ATTEND THE MEETINGS OR WISH TO WATCH THEM AGAIN, YOU CAN DO SO HERE: SPRING 2021 VIRTUAL GROUP MEETING RECORDINGSClose alert
Toggle search
Toggle menu
Enter your keywords
USER ACCOUNT MENU
* Log in
MAIN NAVIGATION
* About
* History & Impact
* Mission & Values
* Leadership
* Support SWOG
* Join SWOG
* Patient Resources
* Policies & Procedures* Contact Us
* The SWOG Network
* How We Work
* Our Staff
* Our Advocates
* Our Partners
* News & Events
* News
* SWOG Stories
* SWOG Meetings
* For Press
* Clinical Trials
* Biospecimen Resources * Clinical Trials Search* Publications
* Institutions
* Quality Assurance & Audits * Serious Adverse Events * Protocol WorkbenchMAIN NAVIGATION
* About
* Overview
* History & Impact
* Mission & Values
* Leadership
* Support SWOG
* Join SWOG
* Patient Resources
* Policies & Procedures* Contact Us
* The SWOG Network
* Overview
* How We Work
* Our Staff
* Our Advocates
* Our Partners
* News & Events
* Overview
* News
* SWOG Stories
* SWOG Meetings
* For Press
* Clinical Trials
* Overview
* Biospecimen Resources * Clinical Trials Search* Publications
* Institutions
* Quality Assurance & Audits * Serious Adverse Events * Protocol WorkbenchMAIN NAVIGATION
* About Toggle submenu* History & Impact
* Mission & Values
* Leadership
* Support SWOG
* Join SWOG
* Patient Resources
* Policies & Procedures* Contact Us
* The SWOG Network Toggle submenu* How We Work
* Our Staff
* Our Advocates
* Our Partners
* News & Events Toggle submenu* News
* SWOG Stories
* SWOG Meetings
* For Press
* Clinical Trials Toggle submenu * Biospecimen Resources * Clinical Trials Search* Publications
* Institutions
* Quality Assurance & Audits * Serious Adverse Events * Protocol WorkbenchUSER ACCOUNT MENU
* Log in
HOMEPAGE
PUBLIC POWERED CANCER RESEARCHTODAY
36
open trials
1,243
member sites
226,609
patients enrolled
Raymond Osarogiagbon, MD, SWOG Primary Investigator, Baptist Memorial Health Care/Mid-South MU-NCORP Raymond Osarogiagbon, MD SWOG Primary Investigator, Baptist Memorial Health Care/Mid-South MU-NCORP Scroll DownTODAY
36
open trials
1,243
member sites
226,609
patients enrolled
LOGIN
Enter your CTEP credentialsLogin Help
SEARCH
Search through clinical trials designed and conducted by our worldwide network of researchers. GROUP MEETING REGISTRATION Attend a meeting to collaborate with our member experts and get the latest trial information, tools, and training.GIVE
Support our research by donating to our public charity, The Hope Foundation for Cancer Research.NEWS & STORIES
Show More
The Front Line
May 28, 2021
DIVERSITY, EQUITY, INCLUSION: PERMEATING SWOG RT @LeeJonesMBA : I totally agree! @SWOG #patientadvocateswork alongside
researchers to design and carry out #clinicaltrialsbetter accepte…
10 hours ago
SWOG Cancer Research@swog
Announcement
Mar 19, 2020
COVID-19 INFORMATION CLEARINGHOUSEThe Front Line
Jun 4, 2021
NURSE SCIENTISTS & APPS: THEIR GROWING IMPACTPress Release
Jun 3, 2021
IMMUNOTHERAPY CAN LOWER MELANOMA RELAPSE RISKPress Release
Jun 1, 2021
SWOG RESEARCHERS ADVANCE CANCER CARE AT ASCOThe Front Line
May 28, 2021
DIVERSITY, EQUITY, INCLUSION: PERMEATING SWOG RT @LeeJonesMBA : I totally agree! @SWOG #patientadvocateswork alongside
researchers to design and carry out #clinicaltrialsbetter accepte…
10 hours ago
SWOG Cancer Research@swog
PrevNext
1
2
3
4
5
6
MORE ABOUT SWOG CANCER RESEARCH NETWORKCLINICAL TRIALS
Learn more about cancer clinical trials and how to find oneOUR NETWORK
Find out about our members at over 1,000 institutions worldwideSWOG MEETINGS
Get the latest information on our biannual member meetings Jo Horn, President & CEO, The Hope Foundation for Cancer ResearchOUR GOAL
SIGNIFICANTLY IMPROVE LIVES through cancer clinical trials and translational research. We TEST new ways to prevent and treat cancer. We STUDY ways to improve the care cancer patients receive, and improve quality of life for survivors once initial treatment ends - relieving pain, promoting physical and mental health, and creating better end-of-life care.GIVE
Jo Horn, President & CEO, The Hope Foundation for Cancer ResearchBack Button Refresh
FOOTER: SOCIAL LINKS* YouTube
Copyright © 2021
FOOTER
* Disclaimer
* FISMA
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0